Please use this identifier to cite or link to this item: https://hdl.handle.net/2440/46749
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCrompton, R.-
dc.contributor.authorClifton, V.-
dc.contributor.authorBisits, A.-
dc.contributor.authorRead, M.-
dc.contributor.authorSmith, R.-
dc.contributor.authorWright, I.-
dc.date.issued2003-
dc.identifier.citationJournal of Clinical Endocrinology and Metabolism, 2003; 88(11):5427-5432-
dc.identifier.issn0021-972X-
dc.identifier.issn1945-7197-
dc.identifier.urihttp://hdl.handle.net/2440/46749-
dc.descriptionCopyright © 2003 by The Endocrine Society-
dc.description.abstractCRH plays a central role as a mediator of the hypothalamic-pituitary-adrenal axis and stress response and is a potent vasodilator. Previously, we have shown that CRH causes a gender-specific vasodilation in human skin, although the mechanism by which CRH operates is unclear. CRH causes mast cell degranulation in rat skin. As such, histamine and other mast cell-derived factors may be indirectly responsible for the vasodilatory effects of CRH, although CRH is also known to act directly on the vasculature. CRH-induced vasodilation in human skin was examined using laser Doppler flowmetry and iontophoresis in adult females. CRH (1 nM) was administered iontophoretically to the forearm, and blood flow was measured simultaneously in the same area by laser Doppler. CRH-induced dilation of the skin microvasculature was significantly reduced in the presence of the mast cell degranulation inhibitor, sodium cromoglycate, the histamine H1-antagonist, promethazine, or the H2-antagonist, ranitidine. CRH-induced dilation was also significantly reduced in the presence of the nitric oxide synthase inhibitor, N-nitro-L-arginine methyl ester, or the cyclooxygenase inhibitor, piroxicam. These findings provide novel evidence that CRH-induced vasodilation in human skin occurs via mast cell degranulation and is principally mediated by histamine and, to a lesser extent, by prostacyclin and nitric oxide.-
dc.description.statementofresponsibilityRenee Crompton, Vicki L. Clifton, Andrew T. Bisits, Mark A. Read, Roger Smith and Ian M. R. Wright-
dc.language.isoen-
dc.publisherEndocrine Society-
dc.source.urihttp://dx.doi.org/10.1210/jc.2003-030377-
dc.subjectMast Cells-
dc.subjectSkin-
dc.subjectHumans-
dc.subjectNitroprusside-
dc.subjectPromethazine-
dc.subjectCorticotropin-Releasing Hormone-
dc.subjectNG-Nitroarginine Methyl Ester-
dc.subjectReceptors, Corticotropin-Releasing Hormone-
dc.subjectHistamine H1 Antagonists-
dc.subjectVasodilator Agents-
dc.subjectEnzyme Inhibitors-
dc.subjectCell Degranulation-
dc.subjectVasodilation-
dc.subjectMiddle Aged-
dc.subjectFemale-
dc.titleCorticotropin-Releasing Hormone Causes Vasodilation in Human Skin via Mast Cell-Dependent Pathways-
dc.typeJournal article-
dc.identifier.doi10.1210/jc.2003-030377-
pubs.publication-statusPublished-
dc.identifier.orcidClifton, V. [0000-0002-4892-6748]-
Appears in Collections:Aurora harvest 6
Paediatrics publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.